Jessica D. Kindrick

Jessica D. Kindrick

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JKJessica D. Kindrick
Jessica D. Kindrick
DMDavid R. Mole
David R. Mole
Cellular responses to low oxygen (hypoxia) are fundamental to normal physiology and to the pathology of many common diseases. Hypoxia-inducible factor (HIF) is central to this by enhancing the transcriptional activity of many hundreds of genes. The cellular response to HIF is cell-type-specific and is largely governed by the pre-existing epigenetic landscape. Prior to activation, HIF-binding sites and the promoters of HIF-target genes are already accessible, in contact with each other through chromatin looping and display markers of activity. However, hypoxia also modulates the epigenetic environment, both in parallel to and as a consequence of HIF activation. This occurs through a combination of oxygen-sensitive changes in enzyme activity, transcriptional activation of epigenetic modifiers, and localized recruitment to chromatin by HIF and activated RNApol2. These hypoxic changes in the chromatin environment may both contribute to and occur as a consequence of transcriptional regulation. Nevertheless, they have the capacity to both modulate and extend the transcriptional response to hypoxia.

1 August 2025 in Cancer Research Communications
Verified
Journal Article
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often develop resistance to next-generation hormonal therapies that target the androgen receptor (AR) axis (e.g., abiraterone and enzalutamide). A splice variant of AR, AR-V7, is associated with resistance to these inhibitors as well as mCRPC progression and poor prognoses. We embarked upon a high-throughput screen to identify synergistic combinations of targeted therapies using two CRPC cell lines, LNCaP95 and VCaP-CR. Combinations targeting BCL2L1 (Bcl-xL) (A-1331852 and navitoclax) and MCL1 (S63845) synergistically decreased cell viability and induced apoptotic activity via cleavage of PARP, caspase 3, and caspase 7 across AR-V7–expressing CRPC cell lines (LNCaP95, VCaP-CR, and 22Rv1) and a patient-derived organoid model (LuCaP 167CR). We also explored the use of a Bcl-xL–specific proteolysis-targeting chimera degrader (PROTAC) to minimize platelet toxicity associated with Bcl-xL inhibitors. We showed similar synergistic efficacy with the Bcl-xL–targeting PROTAC in combination with S63845 in the three-dimensional spheroid models. Our findings support further preclinical development of Bcl-xL and Mcl-1 inhibitors for mCRPC. Significance: Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7–expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7–expressing CRPC.

15 April 2026 in Nature Chemistry
Verified
Journal Article
Open access
PDF file
RBRoman Belle
Roman Belle
JBJohn-Paul Bukowski
John-Paul Bukowski
RSRachel Schiller
Rachel Schiller
RCRonald Cutler
Ronald Cutler
ESEidarus Salah
Eidarus Salah
CSChristopher J. Schofield
Christopher J. Schofield
Histone modifications, including N ε -lysine acetylation and methylation, play critical roles in the regulation of eukaryotic transcription. The addition of acetyl and methyl groups and removal of acetyl groups to histones involve redox-neutral reactions. Demethylation is O 2 -dependent, as reported for reactions catalysed by the 2-oxoglutarate-dependent hypoxia-inducible factor (HIF) hydroxylases, one of which is structurally related to the Jumonji-C (JmjC) histone demethylases. We screened for substrates of the HIF-regulated JmjC lysine demethylase KDM3A and unexpectedly observed that purified recombinant KDM3A catalyses oxidation of the N ε -acetyl group of the Lys-9 of histone H3 (H3K9ac) giving an N ε -hydroxyacetylated product (H3K9acOH). Here we show that N ε -hydroxyacetyl-lysine is recognized by proteins known to bind to H3K9ac, including histone deacetylases and the YEATS domain-containing AF9. Studies employing an N ε -hydroxyacetyl-lysine selective antibody and mass spectrometry support the cellular relevance of N ε -hydroxyacetyl-lysine. Our combined biochemical and cellular results provide evidence for an unanticipated O 2 -mediated link between histone lysine N ε -acetylation and JmjC catalysis.

21 August 2025
Verified
Other
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
Figure S3 shows the effects of co-treatment of venetoclax with S63845 across 2D culture.

21 August 2025
Verified
Other
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
Dual targeting of Bcl-xL and Mcl-1 leads to synergistic decreases in cell viability in 3D LNCaP95 spheroids and the LuCaP 167CR organoid model. Dual treatment of navitoclax and A-1331852 with S63845 in 3D prostate cancer models. A, Representative images for each treatment condition before treatment and 24, 48, and 72 hours after treatment. B and C, Viability of spheroids measured by 3D CellTiter-Glo after 72 hours of treatment. Plots show mean ± SD. ****, P < 0.0001. LuCaP-167CR organoids were treated with the combination of A-1331852 and S63845 (D–F) or navitoclax and S63845 (G–I). Drug curves (D and G) show mean ± SD. Dose–response matrices (E and H) and Bliss synergy plots (F and I) were generated using the Synergyfinder+ R package to evaluate synergy. All spheroid experiments were completed in triplicate. Organoid experiments had six technical replicates with three biological replicates.

21 August 2025
Verified
Other
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often develop resistance to next-generation hormonal therapies that target the androgen receptor (AR) axis (e.g., abiraterone and enzalutamide). A splice variant of AR, AR-V7, is associated with resistance to these inhibitors as well as mCRPC progression and poor prognoses. We embarked upon a high-throughput screen to identify synergistic combinations of targeted therapies using two CRPC cell lines, LNCaP95 and VCaP-CR. Combinations targeting BCL2L1 (Bcl-xL) (A-1331852 and navitoclax) and MCL1 (S63845) synergistically decreased cell viability and induced apoptotic activity via cleavage of PARP, caspase 3, and caspase 7 across AR-V7–expressing CRPC cell lines (LNCaP95, VCaP-CR, and 22Rv1) and a patient-derived organoid model (LuCaP 167CR). We also explored the use of a Bcl-xL–specific proteolysis-targeting chimera degrader (PROTAC) to minimize platelet toxicity associated with Bcl-xL inhibitors. We showed similar synergistic efficacy with the Bcl-xL–targeting PROTAC in combination with S63845 in the three-dimensional spheroid models. Our findings support further preclinical development of Bcl-xL and Mcl-1 inhibitors for mCRPC.Significance:Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7–expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7–expressing CRPC.